Literature DB >> 28391334

Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis.

Sanjeev Sethi1, Ladan Zand2, An S De Vriese3, Ulrich Specks4, Julie A Vrana1, Siddak Kanwar5, Paul Kurtin1, Jason D Theis1, Andrea Angioi2, Lynn Cornell1, Fernando C Fervenza2.   

Abstract

BACKGROUND: Complement activation plays an important role in the pathophysiology of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), although it remains unclear which pathway is activated. Whether pauci-immune necrotizing crescentic glomerulonephritis (pauci-immune GN) with negative ANCA serology is part of the spectrum of AAV or a different disease entity is essentially unknown.
METHODS: We used proteomic analysis to delineate the complement profile in a series of 13 kidney biopsies of patients with pauci-immune GN, with either proteinase 3 (PR3) (five patients) or myeloperoxidase (MPO) antibodies (four patients) or with consistently negative ANCA serology (four patients). Immunofluorescence staining of glomeruli was essentially negative in the PR3-ANCA and MPO-ANCA groups, while a mild staining for C3 was seen in the ANCA-negative cases. No electron-dense deposits were found in the PR3-ANCA and MPO-ANCA groups, but mesangial and few subepithelial deposits were clearly present in the ANCA-negative specimens.
RESULTS: Mass spectrometry revealed low spectra numbers for C3 and immunoglobulins in both PR3-positive and MPO-positive patients with minimal or no C4 and C9. In contrast, larger spectra numbers for C3, moderate spectra numbers for C9, complement factor H-related protein-1 and low spectra numbers for C4, C5 and immunoglobulins were found in the ANCA-negative cases.
CONCLUSION: While complement activation is noted in AAV, the complement activation appears to be more prominent in the ANCA-negative glomerulonephritis. The larger amount of C3 and moderate amount of C9 in the ANCA-negative glomerulonephritis implies activation of the alternate and terminal pathway of complement, suggesting that this entity may be caused or promoted by a genetic or acquired defect in the alternative pathway.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  alternative pathway; anti-neutrophil cytoplasmic antibody; complement; crescentic glomerulonephritis; mass spectrometry; pauci-immune

Mesh:

Substances:

Year:  2017        PMID: 28391334     DOI: 10.1093/ndt/gfw299

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

2.  A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers.

Authors:  Sidharth Kumar Sethi; Abhyuday Rana; Shyam Bihari Bansal; Alka Rana; Dinesh Kumar Yadav; Kritika Soni; Marie-Agnès Dragon-Durey; Rupesh Raina; Vijay Kher
Journal:  Pediatr Nephrol       Date:  2020-10-15       Impact factor: 3.714

3.  Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  L Cheng; S-J Gou; H-Y Qiu; L Ma; P Fu
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

Review 4.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

5.  Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis.

Authors:  Michiko Aoki; Dedong Kang; Akira Katayama; Naomi Kuwahara; Shinya Nagasaka; Yoko Endo; Mika Terasaki; Shinobu Kunugi; Yasuhiro Terasaki; Akira Shimizu
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

6.  Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort.

Authors:  Alvise Berti; Emilie Cornec-Le Gall; Divi Cornec; Marta Casal Moura; Eric L Matteson; Cynthia S Crowson; Aishwarya Ravindran; Sanjeev Sethi; Fernando C Fervenza; Ulrich Specks
Journal:  Nephrol Dial Transplant       Date:  2019-09-01       Impact factor: 5.992

Review 7.  A potential pathogenic role of interleukin-6 in a child with ANCA-negative pauci-immune crescentic glomerulonephritis: case report and literature review.

Authors:  Ling Hou; Lu Yin; Yubin Wu; Chengguang Zhao; Yue Du
Journal:  BMC Nephrol       Date:  2021-08-23       Impact factor: 2.388

Review 8.  C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders.

Authors:  Kultigin Turkmen; Ismail Baloglu; Hakan Ozer
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

Review 9.  Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Nestor Oliva-Damaso; Andrew S Bomback
Journal:  Clin Kidney J       Date:  2020-12-29

10.  Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis developed from ANCA negative renal limited vasculitis: A case report.

Authors:  Xiao-Li Li; Peng-Cheng Xu; Tong Chen; Tie-Kun Yan; Jian-Qing Jiang; Jun-Ya Jia; Li Wei; Wen-Ya Shang; Shui-Yi Hu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.